Product InnovationUS Hips has recently outperformed the market, following the same trend as US Trauma last year, after the introduction of the short-stem CATALYSTEM hip platform.
Sales GrowthThe company's third-quarter sales growth is strong, with an increase of 7.6%, and there are no negative impacts from trading days, indicating a positive outlook.
Shareholder ValueA $500 million share buyback is planned, indicating confidence in the company's financial health and potential to return value to shareholders.